Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ABCL 
Abcellera Biologics Inc (ABCL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: ABCL (4-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $9.33
1 Year Target Price $9.33
| 6 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 5.19% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.46B USD | Price to earnings Ratio - | 1Y Target Price 9.33 |
Price to earnings Ratio - | 1Y Target Price 9.33 | ||
Volume (30-day avg) 9 | Beta 0.7 | 52 Weeks Range 1.89 - 6.51 | Updated Date 11/5/2025 |
52 Weeks Range 1.89 - 6.51 | Updated Date 11/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.56 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-11 | When - | Estimate -0.1363 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -290.24% |
Management Effectiveness
Return on Assets (TTM) -10.96% | Return on Equity (TTM) -15.64% |
Valuation
Trailing PE - | Forward PE 27.47 | Enterprise Value 1376022819 | Price to Sales(TTM) 44.27 |
Enterprise Value 1376022819 | Price to Sales(TTM) 44.27 | ||
Enterprise Value to Revenue 41.85 | Enterprise Value to EBITDA 5.3 | Shares Outstanding 298832913 | Shares Floating 202749166 |
Shares Outstanding 298832913 | Shares Floating 202749166 | ||
Percent Insiders 22.94 | Percent Institutions 38.7 |
Upturn AI SWOT
Abcellera Biologics Inc
Company Overview
History and Background
AbCellera Biologics Inc. was founded in 2012 in Vancouver, Canada. It pioneered a technology platform for antibody discovery, partnering with pharmaceutical and biotechnology companies. AbCellera went public in December 2020.
Core Business Areas
- Antibody Discovery: AbCellera focuses on discovering therapeutic antibodies for its partners using its integrated technology platform. This includes target identification, antibody generation, screening, and characterization.
Leadership and Structure
AbCellera is led by CEO Carl Hansen. The organizational structure includes research and development, business development, and operations departments.
Top Products and Market Share
Key Offerings
- Therapeutic Antibody Discovery: AbCellera's primary offering is its end-to-end antibody discovery platform. They do not sell products directly. Revenue comes from research fees, milestone payments, and royalties from partnered programs. Competitors include distributed service companies such as Charles River Laboratories (CRL) and WuXi Biologics (2269.HK).
Market Dynamics
Industry Overview
The therapeutic antibody discovery market is experiencing strong growth, driven by increased demand for novel biologics and advances in technologies like AI and high-throughput screening.
Positioning
AbCellera aims to be a leader in AI-powered antibody discovery, differentiating itself with its integrated platform and high throughput capabilities.
Total Addressable Market (TAM)
The total antibody therapeutics market is estimated to be in the hundreds of billions. AbCellera is positioned to capture a portion of the early discovery segment, estimated at $5-10 billion annually.
Upturn SWOT Analysis
Strengths
- Integrated Technology Platform
- AI-powered Discovery
- High Throughput Capabilities
- Strong Partner Network
- Successful Track Record
Weaknesses
- Reliance on Partnered Programs
- High Operating Costs
- Relatively Young Company
- Cash Burn Rate
Opportunities
- Expanding into New Therapeutic Areas
- Developing Proprietary Antibody Programs
- Strategic Acquisitions
- Increased Adoption of AI in Drug Discovery
Threats
- Competition from Established CROs
- Technological Advancements by Competitors
- Clinical Trial Failures of Partnered Programs
- Economic Downturn affecting R&D Spending
Competitors and Market Share
Key Competitors
- CRL
- WuXi Biologics (2269.HK)
Competitive Landscape
AbCellera aims to differentiate itself from traditional CROs with its AI-powered platform and end-to-end capabilities. It faces competition from established players with larger scale and broader service offerings.
Growth Trajectory and Initiatives
Historical Growth: Revenue growth has been inconsistent, driven by milestone achievements. The company's stock price has declined significantly since its IPO.
Future Projections: Analyst estimates vary widely, depending on the success of partnered programs and new business development efforts. Revenue is expected to grow, but profitability remains uncertain.
Recent Initiatives: AbCellera is investing in expanding its technology platform, pursuing strategic partnerships, and exploring proprietary antibody programs.
Summary
AbCellera is an innovative antibody discovery company with a promising technology platform. Its AI-powered approach has the potential to disrupt the industry. However, it faces challenges related to profitability, dependence on partnered programs, and competition. Future success hinges on securing more successful partnerships and achieving financial stability.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Filings (SEC), Analyst Reports, Press Releases
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Abcellera Biologics Inc
Exchange NASDAQ | Headquaters Vancouver, BC, Canada | ||
IPO Launch date 2020-12-11 | CEO, President & Chairperson Dr. Carl L.G. Hansen Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 596 | Website https://www.abcellera.com |
Full time employees 596 | Website https://www.abcellera.com | ||
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.